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PREVALENCE OF FIBROMYALGIA IN RUSSIA
Le Lay K1, Nasonov E2, Soldatov D3, Taieb C1
1Pierre Fabre, Boulogne, France, 2Rheumatology Institute, Moscou, Russia, 3Pierre Fabre 
Laboratories, Moscou, Russia
OBJECTIVES: To assess the estimated prevalence of ﬁ bromyalgia syndrome (FM)
among the adult population in the general population in Russia, using the London
Fibromyalgia Epidemiology Study – Screening Questionnaire (LFESSQ) and American
College of Rheumatology (ACR) classiﬁ cation criteria. METHODS: The validated 
Russian version of the LFESSQ was administered to a representative community sample 
of 1,610 subjects aged over 15 years, selected by the quota method. A positive screen 
was deﬁ ned as: (1) meeting the 4-pain criteria alone (LFESSQ-4), or meeting both the
4-pain and 2-fatigue criteria (LFESSQ-6). The questionnaire was submitted to a sample 
of rheumatology outpatients (n  399), who were then examined by a trained rheu-
matologist to conﬁ rm or exclude the diagnosis of FM according to the 1990 American 
College of Rheumatology criteria. The prevalence of FM in the general population
was estimated by applying the predictive positive value to eligible community subjects
(i.e., positive screens). RESULTS: In the community sample, 13.8% screened positive
for LFESSQ-6 (18.4% in females and 8.1% in males respectively). Among rheumatol-
ogy outpatients, 43.6% were screened positive (44.3% in females and 40.5% in males
respectively), whereas 6.5% were conﬁ rmed FM cases. The prevalence of FM was 
estimated at 2.1% (95% CI: 1.4%–2.8%, 2.8% in females and 1.2% in males respec-
tively) in the Russian general population. CONCLUSIONS: Our ﬁ ndings are in
agreement with those of earlier national survey reports. A point prevalence of 2.1%
would translate in approximately 2.5 million of patients with FM in Russia.
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THE RELATIONSHIP BETWEEN SURGICAL DELAY OVER 24 HOURS AND
30 DAYS MORTALITY FOLLOWING FEMORAL NECK FRACTURE IN THE
PRESENCE OF DIFFERENT CO-MORBIDITIES
Sebestyén A1, Boncz I2, Molnár A1, Ko˝rösi L3, Kriszbacher I4, Brodszky V5, Gulácsi L5, 
Sándor J2
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, 
Pécs, Hungary, 3National Health Insurance Fund Administration (OEP), Budapest, Hungary, 
4University of Pécs, Pecs, Hungary, 5Corvinus University of Budapest, Budapest, Hungary
OBJECTIVES: The aim of our study is to analyze the relationship between surgical
delay over 24 hours and 30 days mortality following femoral neck fracture in the 
presence of different co-morbidities in patients aged over 60 years. METHODS: Data
were derived from the database of the National Health Insurance Fund Administration 
according to the ICD 10th revision’s S7200 code. The study included patients aged
over 60 years old discharged from inpatient care institutions following the primary 
treatment of femoral neck fractures. The patients with polytrauma were excluded from
the study. In case of surgical delay six hours mortality was the reference. Data were
evaluated according to sex, age, type of fracture, patient turnover of institutions, type
of surgery, early complications, hospital type, day of operation. The following co-
morbidities were included into the analysis: C00-C97, D60-D64, E10-E16, F00-F99, 
G20-G26, G80-G83, I10-I15, I20-I25, I30- I52, I60-I69, I70, J00-J22, J40-J47, L89, 
N30-N39). Statistical analysis has been performed by logistic regression (Odds
Ratio(95%CI), p  0,05). RESULTS: Altogether 3783 patients were involved into
the study. Surgical delay (24 h/0–6 h) OR  1.5009, p  0.0095. The following co-
morbidities (ICD codes with OR and p value) proved to be statistically signiﬁ cant 
predictors: C00-C97: 2,6381(0.0274), G80-G83: 2.5984(0.0224), I20-I25:
1.6125(0.0438), I30-I52: 2.2758(0.0246), I70: 1.7281(0.0328), J00-J22: 2.2884(0.04), 
J40-J47: 2.3204(0.0141). CONCLUSIONS: Longer than 24 hours surgical delay sig-
niﬁ cantly increased the risk of 30 days mortality compared to 6 hours delay. The
longer than 24 hours surgical delay of treatment of elderly femoral neck fracture
proved to be statistically signiﬁ cant predictors of 30 days mortality: malignancies,
cerebral paralyzed disorders, ischemic and other heart diseases, arteriosclerosis, infec-
tions of the upper and lower respiratory system and chronic diseases of the lower 
respiratory system. In order to decrease the risk of early mortality it is essential strive
after earliest surgical treatment with special respect the high risk patient group with 
co-morbidities.
PMS15
RELATIONSHIP BETWEEN SURGICAL INTERVENTION TYPE AND 30 
DAYS MORTALITY OF ELDERLY FEMORAL NECK FRACTURE IN THE
PRSENCE OF DIFFERENT CO-MORBIDITIES
Sebestyén A1, Boncz I2, Molnár A1, Ko˝rösi L3, Kövi R3, Kriszbacher I4, Oláh A4, Pentek M5, 
Sándor J2
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, 
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OBJECTIVES: The aim of our retrospective study is to analyze the relationship 
between type of operation and 30 days mortality following femoral neck fracture in
the presence of different co-morbidities in patients aged over 60 years. METHODS:
Data were derived from the database of the National Health Insurance Fund Admin-
istration according to the ICD 10th revision’s S7200 code. The study included patients
aged over 60 years old discharged from inpatient care institutions following the
primary treatment of femoral neck fractures. The patients with polytrauma were 
excluded from the study. Osteosynthesis was compared to arthroplasty as reference
surgical method. Data were evaluated according to sex, age, type of fracture, patient
turnover of institutions, surgical delay, early complications, hospital type, day of 
operation. The following co-morbidities were included into the analysis: C00-C97, 
D60-D64, E10-E16, F00-F99, G20-G26, G80-G83, I10-I15, I20-I25, I30- I52, I60-
I69, I70, J00-J22, J40-J47, L89, N30-N39). Statistical analysis has been performed 
by logistic regression (Odds Ratio[95%CI], p  0.05). RESULTS: Altogether 3783 
patients were involved into the study. Type of surgical intervention (osteosynthesis/
arthroplasty) OR: 1.7265, p: 0.0128. The following co-morbidities (ICD codes 
with OR and p value) proved to be statistically signiﬁ cant predictors: I10-I15:
2,0759(0.0136), I60-I69: 2.5104(0.0498), J40-J47: 2.8177(0.0305). CONCLU-
SIONS: Osteosynthesis signiﬁ cantly increased the risk of 30 days mortality compared
to arthroplasty. Osteosynthesis treatment of elderly femoral neck fracture proved to 
be statistically signiﬁ cant predictors of 30 days mortality: cerebrovascular disorders 
and chronic diseases of the lower respiratory system. A possible explanation of the 
difference in mortality can be that because of the higher risk of arthroplasty more
healthy patients are selected for arthroplasty, while patient with poorer general health
status undergo osteosynthesis having lower surgical risk.
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ESTIMATION OF LIFE EXPECTANCIES AND LOSS OF LIFE
EXPECTANCIES FOR WORKERS WITH PERMANENT OCCUPATIONAL
DISABILITY OF UPPER AND LOWER LIMBS: A FOLLOW-UP STUDY OF
69,964 WORKERS FOR 21 YEARS
Lin SH1, Lee HY1, Chang YY1, Jang Y1, Wang JD2
1National Taiwan University Hospital, Taipei, Taiwan, 2National Taiwan University, College of 
Public Health, Taipei, Taiwan
OBJECTIVES: This study intends to estimate the life expectancies and loss of life 
expectancies for workers with permanent occupational disability of upper and lower
limbs in Taiwan. METHODS: We collected all cases of permanent occupational dis-
ability from the database of compensation claim of Bureau of Labor Insurance between 
1986 and 2006, which were linked with the national mortality registry to obtain the 
survival function. We generated survival curve for age- and sex-matched reference 
population from the life table of the Taiwan general population in 2000 through Monte 
Carlo method. Lifetime survival of the workers (up to 1000 months) were obtained
using linear extrapolation of a logit-transformed curve of the survival ratio between 
the workers and reference populations. RESULTS: The life loss for workers with leg
amputation and injury were 51.5 o 19.7, and 98.0 o 16.8 life-months, respectively,
while those for workers with arm amputation and injury were 153.9 o 63.1 and 81.5 
o 29.3, respectively. However, workers with permanent toes and ﬁ ngers showed no 
statistically signiﬁ cant loss of life expectancies compared with the general populations.
CONCLUSIONS: Workers with permanent occupational disability of arm or leg suf-
fered from signiﬁ cant loss of life expectancies, which should be considered for com-
pensation and cost-effectiveness analysis of prevention for these populations.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
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NATIONAL COST OF ILLNESS STUDY COMPARING VETERAN PATIENTS
WITH GOUT TO THOSE WITH DIFFICULT TO MANAGE GOUT
Raisch DW1, Campbell HM2, Khan N3, Rice J2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2Department of 
Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 3University of New
Mexico, Albuquerque, NM, USA
OBJECTIVES: To measure the health care utilization of US veteran patients with gout 
and to determine additional costs associated with difﬁ cult to manage gout (DMG).
METHODS: Using diagnostic codes (ICD-9 CD  274.XX), we identiﬁ ed patients 
with gout in 2004 from the national Veterans Affairs Health Care System (VA) data-
bases. We then collected all administrative data (demographic, inpatient and outpa-
tient care, pharmacy, laboratory, and tests) for these patients over the years 2004–2006.
DMG patients were identiﬁ ed by diagnostic codes associated with complications of 
the skin (tophi), eye, nerve, and kidney. We created data summaries for each patient 
by year; including diagnoses, treatments, drug therapies, laboratory tests, and surger-
ies. RESULTS: There were 200,772 patients identiﬁ ed in 2004. Each year, heathcare 
costs per patient were signiﬁ cantly higher (Kruskal Wallis tests, P  0.001) for DMG 
versus other gout patients: inpatient costs in 2006. In addition DMG patients were 
signiﬁ cantly (P  0.001), had higher Charlson co-morbidity scores and were more 
likely to have concomitant cardiovascular, renal, and liver diseases. A limitation of 
the study is the lack of speciﬁ city of diagnostic codes for complications due to gout, 
which may impact the sample size. CONCLUSIONS: Health care costs are signiﬁ -
cantly higher for DMG patients. We note that increased inpatient plus outpatient costs 
for DMG patients were $10,000 to $16,000 per patient-year. These VA patients also
have signiﬁ cantly more co-morbid conditions than other gout patients.
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ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID
TREATMENT OF OSTEOARTHRITIS – A COMPARISON BETWEEN 
CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL
Svedbom A1, Borgstrom F1, Holmstrom S2, Miltenburger C3
1i3 Innovus, Stockholm, Sweden, 2NicOx, Sophia Antipolis, France, 3i3 Innovus, Berlin, Germany
OBJECTIVES: To quantify and compare the overall adverse event (AE) related costs 
and their constituents associated with celecoxib and traditional NSAID treatment in
osteoarthritis (OA). METHODS: Using an amended version of a recent NICE Markov
Abstracts A67
model (ﬁ ve-year horizon, three-month cycles) evaluating NSAID treatment in OA, the
overall AE related costs and their constituents associated with celecoxib and ibuprofen 
treatment were quantiﬁ ed and compared. The individual costs (11 in total) were
aggregated to four categories relevant to OA treatment: (i) costs directly attributable
to clinically signiﬁ cant gastrointestinal (GI) AEs; (ii) costs directly attributable to dys-
pepsia; (iii) costs associated with myocardial infarction (MI); and (iv) co-medication
(mainly proton pump inhibitors) costs. The model, which has a health care perspective,
was populated with UK data and a discount rate of 3.5% per year was used. Except 
for the MI risks which were adjusted for age, all absolute and relative risks were taken 
from a meta-analysis in a recent NICE HTA report. Costs were aggregated to 1000 
patients on treatment. RESULTS: Although 9 of the 11 adverse event related individual 
costs were lower with celecoxib than ibuprofen treatment, the overall cost difference 
(a42,640 in favor of celecoxib) was attenuated by the relatively high MI related costs 
associated with celecoxib treatment (a92,734). CONCLUSIONS: Whilst the GI safety 
proﬁ le of celecoxib yields cost advantages, the MI costs associated with celecoxib 
treatment weakens the effect on overall adverse event related costs resulting from the
beneﬁ cial GI safety proﬁ le.
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DRUG UTILIZATION AND SPENDING TRENDS OF BISPHOSPHONATE
MEDICATIONS MEDICAID PROGRAMS IN THE UNITED STATES
Berry E1, Guo JJ1, Kelton CM1, Shiyanbade H2, Knight D3, Heaton PC1
1University of Cincinnati, Cincinnati, OH, USA, 2university of Cincinnati, cincinnati, OH, USA, 
3University of Cincinnati, cincinnati, OH, USA
OBJECTIVES: Eight million women and two million men are afﬂ icted with osteopo-
rosis in the United States. There are additional 34 million people exhibiting low bone
mass at risk for the development of osteoporosis. The purpose of this study was to
describe the drug utilization and spending trends for bisphosphonate and other alter-
native osteoporosis medications in the Medicaid program. METHODS: Using a ret-
rospective and descriptive study, Medicaid pharmacy claims data extracted from the
Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 regarding
quarterly number of prescriptions, units usage, reimbursement amount, and reim-
bursement per prescription for the oral bisphosphonates, injectable bisphosphonates, 
and alternative osteoporosis medications. Drugs were identiﬁ ed using their respective 
national drug codes (NDC). RESULTS: Risedronate accounted for 27% of all bisphos-
phonates prescriptions while alendronate accounted for the vast majority of bisphos-
phonate prescriptions with approximately 70% of the market over the 1991–2007 
timeframe. Both alendronate and risedronate together accounted for approximately
92% of all reimbursements for both oral and injectable bisphosphonates during the 
study period. Alendronate’s market share, as measured by total reimbursement, has 
been steadily declining from third quarter of 2004 to the third quarter of 2007, 
accounting for approximately 57% of total reimbursements, contrary to the roughly
83% of all reimbursements from the fourth quarter of 1996 to the second quarter of 
2004. CONCLUSIONS: Market share for the leading brand drugs has steadily
declined with the introduction of generic competition as measured by overall utiliza-
tion and total reimbursement, such as risedronate competing with alendronate in the 
bisphosphonate market and raloxifene competing with calcitonin-salmon in the alter-
native osteoporosis market. Examination of the Medicaid data also revealed a strident 
market shift in utilization following the fourth quarter of 2005, resulting from the
switching of dual eligibles from Medicaid to Medicare Part D.
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A COMPARISON OF DIFFERENT METHODS OF ESTIMATING FRACTURE 
RISK AND FRACTURE RISK REDUCTION IN COST-EFFECTIVENESS
ANALYSES OF THE OSTEOPOROSIS TREATMENT BAZEDOXIFENE
Borgström F1, Coelho J2, Ström O2, McCloskey E3, Odén A4, Johansson H5, Kanis JA6
1i3 Innovus, Stockholm, Sweden, 2i3 Innovus, Stockholm, Stockholm, Sweden, 3Osteoporosis 
Centre, Shefﬁ eld, Shefﬁ eld, UK, 4University of Shefﬁ eld, Gothenbourg, Gothenbourg, Sweden, 
5University of Shefﬁ eld, Gothenbourg, Gothebourg, Sweden, 6University of Shefﬁ eld, Shefﬁ eld, 
Shefﬁ eld, UK
OBJECTIVES: To compare the traditionally used approach for fracture risk assess-
ment in cost-effectiveness analysis (CEA) compared to the use of FRAX models 
based on multiple individual clinical risk factors (CRFs) using the osteoporosis treat-
ment bazedoxifene. METHODS: In CEA of osteoporosis the fracture risk has tradi-
tionally been calculated with risk-adjustments based on age, bone mineral density
(BMD) and prior fracture. The treatment effect has been derived from clinical trials 
and the same efﬁ cacy has been assumed irrespective of the fracture risk of the popula-
tion. A novel approach to fracture risk assessment considers the contribution of 8 
individual CRFs on fracture risk and mortality using the FRAX-tool. The application 
of FRAX to clinical trial populations has shown that treatment efﬁ cacy increases
with higher fracture risk. The cost-effectiveness was estimated in a Markov cohort 
model with US data using a health care perspective. The CEA compared the osteopo-
rosis treatment bazedoxifene (BZA) to no treatment in women with a T-score for
femoral neck BMD of 2.5SD and previous fracture. Using the old approach BZA 
was set to reduce the risk of vertebral fracture by 42% based on the overall analysis 
of the phase III study. Using the FRAX-approach the vertebral fracture risk reduction
varied depending on pre-hoc fracture probability in the target population and was 
estimated at 59%. The relative risk of a vertebral fracture compared to the general
population was 3.96 and 1.82 with the old and FRAX-approach, respectively. 
RESULTS: The cost per QALY gained with bazedoxifene treatment was estimated at 
$54,712 using the old approach and $33,650 using the FRAX-approach. This is due
to differences in the assessment of fracture risk efﬁ cacy, fracture risk and mortality. 
CONCLUSIONS: The advent of more accurate assessment of fracture risk assessment
and its use as a determinant of efﬁ cacy has important consequences for CEA.
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ECONOMIC EVALUATION OF THE USE OF HYLAN G-F 20 IN THE
HANDLING OF SEVERE KNEE OSTEOARTHROSIS
Salinas Escudero G1, Idrovo J2, Zapata L2, Herrera Rodriguez G3
1Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, 2Guia 
Mark, Mexico, DF, Mexico, 3Genzyme, Mexico, DF, Mexico
OBJECTIVES: Knee osteoarthrosis is a multifactorial, progressive and incurable rheu-
matic ailment; most treatments look for a maximum recovery of mobility and func-
tionality of the knee joint, with a minimum risk possibility. Due to its high cost and 
invasive character, gonarthrosis surgical treatment is reserved, according to the clinical
practice guidance available in Mexico, for severe pain and joint functionality limita-
tion cases; deﬁ ned as knee osteoarthrosis present in IV degree, or functional class III
onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs.
intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. 
METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypotheti-
cal cohort behavior of patients with severe knee osteoarthrosis for a period of two 
years, from the perspective of the health service supplier. Costs were estimated using 
prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US 
dollar). RESULTS: With Hylan G-F 20, 94.6% of patients did not require surgery 
during the analysis period vs. 50%, in the case of those under intraarticular steroid 
treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular ste-
roids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 
and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as
dominant alternative. Different sensitivity analyses corroborate the dominance rela-
tionship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS:
Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment 
to withhold surgery in patients with severe knee osteoarthrosis.
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COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS. RITUXIMAB IN
PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO
Gao X1, Hwang S2, Carpiuc KT1, Stephens JM1, Sato R2, Singh A2, Rivera R3, García E3, 
Bierschwale H3
1PharMerit North America LLC, Bethesda, MD, USA, 2Wyeth Research, Collegeville, PA, USA, 
3Wyeth Mexico, Naucalpan, Mexico, Mexico
OBJECTIVES: To determine the cost-effectiveness of etanercept plus methotrexate
(MTX) versus rituximab plus MTX in the treatment of rheumatoid arthritis (RA)
patients from a payer’s perspective in Mexico. METHODS: A literature-based decision 
analytic model was developed to compare the cost and effectiveness of etanercept
25 mg twice-weeklyMTX versus rituximab 2 r 500 mg infusionMTX and ritux-
imab 2 r 1000 mg infusionMTX (labeled dosage) in RA patients with an inadequate
response to disease-modifying anti-rheumatic drugs. The primary measure of clinical
outcomes was based on remission (Disease Activity Score 28 joint count 2.6). The 
model incorporated major and minor infectious events, discontinuation due to inade-
quate efﬁ cacy or adverse event, and rituximab re-treatment within the one year time-
horizon. Data from clinical trials (TEMPO and SERENE) were used. Drug and 
resource-use costs were based on government-reported public costs. Sensitivity analy-
sis was conducted by varying efﬁ cacy and cost parameters by o 30%. RESULTS:
The annual total therapy cost for rituximab was MEX$74,543 (2 r 500 mg) 
and MEX$137,223 (2 r 1000 mg), and MEX$119,133 for etanercept. The incre-
mental cost-effectiveness ratio (ICER) of etanercept vs. rituximab 2 r 500 mg was 
MEX$201,581 per additional patient achieving remission. Etanercept was cost saving 
compared to rituximab 2 r 1000 mg. With a hypothetical budget of MEX$10,000,000
for rituximab or etanercept, the number of patients achieving remission would be 7
(2 r 500 mg) and 4 (2 r 1000 mg) for rituximab and 23 for etanercept. Sensitivity
analysis showed that etanercept continued to have more patients achieving remission 
than rituximab (for both dosage forms) even if drug cost and efﬁ cacy were varied o
30%, given a deﬁ ned budget. CONCLUSIONS: The results suggest that etanercept 
appears to be cost-effective compared to rituximab. For the labeled and commonly 
used rituximab dosage (2 r 1000 mg), etanercept appears to be a cost-saving alterna-
tive. These ﬁ ndings were robust for plausible ranges of effectiveness and drug acquisi-
tion costs.
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AN ECONOMIC ANALYSIS COMPARING THREE COMBINATIONS
OF TUMOR NECROSIS FACTOR-ALPHA AGENTS FOR THE
TREATMENT OF RHEUMATOID ARTHRITIS
Agarwal SJ, Sansgiry SS, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: Purpose of the study was to conduct a cost-efﬁ cacy analyses between 
three combinations of Tumor Necrosis Factor-Alpha agents used in treatment of 
rheumatoid arthritis. The study compared adalimumab plus methotrexate 
(ADALMTX), inﬂ iximab plus methotrexate (INFLMTX), etanercept plus metho-
trexate (ETANMTX), with methotrexate (MTX) monotherapy (control). METHODS:
The study was conducted from the patients’ perspective. Costs calculated for a period 
of one year included direct medical costs (drug acquisition costs, monitoring costs,
and adverse drug event costs) and indirect costs (estimated using human capital 
approach). All costs were calculated in 2007 dollars and adjusted using a discounting
factor of 3%. Outcome of therapeutic options was measured using the American 
